Clinical outcomes from infection with SARS-CoV-2, the cause of the COVID-19 pandemic,
are remarkably variable ranging from asymptomatic infection to severe pneumonia and …

The cytokine release syndrome has been proposed as the driver of inflammation in
coronavirus disease 2019 (COVID-19). However, studies on longitudinal cytokine profiles in …

Background The association of pro-inflammatory markers such as interleukin-6 (IL-6) and
other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest …

The clinical spectrum of COVID-19 varies and the differences in host response
characterizing this variation have not been fully elucidated. COVID-19 disease severity …

An excessive inflammatory response to SARS-CoV-2 is thought to be a major cause of
disease severity and mortality in patients with COVID-19. Longitudinal analysis of cytokine …

Coronaviruses were first discovered in the 1960s and are named due to their crown-like
shape. Sometimes, but not often, a coronavirus can infect both animals and humans. An …

Abstract COVID-19 is associated with 5.1% mortality. Although the virological,
epidemiological, clinical, and management outcome features of COVID-19 patients have …

Background Markedly elevated levels of proinflammatory cytokines and defective type-I
interferon responses were reported in patients with coronavirus disease 2019 (COVID-19) …

We pursued a study of immune responses in coronavirus disease 2019 (COVID-19) and
influenza patients. Compared to patients with influenza, patients with COVID-19 exhibited …

BACKGROUND Elevated levels of inflammatory cytokines have been associated with poor
outcomes among COVID-19 patients. It is unknown, however, how these levels compare …